> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Reviewers Cite Rhopressa Efficacy
- URL: https://www.fdaweb.com/reviewers-cite-rhopressa-efficacy/
- Published: 2017-10-12T12:00:00.000Z
- Updated: 2026-09-14T22:55:42.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5139849

FDA medical reviewers say that Aerie Pharmaceuticals’ Rhopressa (netarsudil ophthalmic solution 0.02%) is effective for its proposed indication of reducing elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. A [briefing document](https://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/DermatologicandOphthalmicDrugsAdvisoryCommittee/UCM579730.pdf?ref=fdaweb.com) released in advance of a 10/13 meeting of the FDA Dermatologic and Ophthalmic Drugs Advisory Company to consider the sponsor’s application says Rhopressa is a Rho kinase inhibitor, a new class of medications proposed to lower intraocular pressure by directly increasing trabecular outflow.

Issues FDA is asking the advisory committee to consider are: 

- whether the drug’s clinical trials support its efficacy for reducing elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension;
- whether the drug’s efficacy as demonstrated in the clinical trials outweighs the safety risks identified for it; and
- suggestions for the product’s draft labeling.